Arpeggio’s technology combines new RNA sequencing technologies with machine learning to better understand drug candidates’ mechanism of action.

After delisting from the New York Stock Exchange, WuXi AppTec has received regulatory approval to be listed in Shanghai.

With Ian Rentsch as CEO, Clinerion plans to grow its global patient network for potential trial recruitment to 310 million by the end of 2018.

ShangPharma Innovation is growing its life science incubator on the West Coast as it looks to help early-stage biomedical work get off the ground.

The CRO just took in Continuum Clinical’s Late Stage research practice and folded it into its Evidence business unit.

Citoxlab is looking to boost its position among Europe’s top nonclinical CROs by buying up Solvo Biotechnology.

The CRO will transfer most of its Pennsylvania-based biologics laboratory functions to a new, 73,000-square-foot site on Devon Park in Wayne.

The new team brings together the CRO’s existing expertise in flow cytometry, immunoassays, cell-based assays and immunotoxicology.